Zipalertinib

Phase 2Small molecule

JJonsson Comprehensive Cancer Center

Zipalertinib is one of 46 small molecule programs targeting Lung Cancer (NSCLC). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung Cancer (NSCLC)Not yet recruiting

Non-Small Cell Lung CancerNot yet recruiting

Lung Cancer (NSCLC)Phase 2

Not yet recruiting

Non-Small Cell Lung CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Neoadjuvant Therapy

SSun Yat-sen University

Phase 3

2 2

Nanocrystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

1 3

WX-0593

Qilu Pharmaceutical Co., Ltd.

Phase 3

4 4

Zipalertinib

JJonsson Comprehensive Cancer Center

Phase 2

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—10

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Lung Cancer (NSCLC)

NCT07802834

Q2 2030

Phase 2Not yet recruiting

Non-Small Cell Lung Cancer

NCT07229339

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Not yet recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT07229339·16 enrolled

Lung Cancer (NSCLC)1 trial

Adjuvant ctDNA-Adapted Personalized Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC

Not yet recruiting·SStanford University·Phase 2·NCT07802834·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Zipalertinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zipalertinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zipalertinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jonsson Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJonsson Comprehensive Cancer Center

Zipalertinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2030

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Lung Cancer (NSCLC)1 trial

References

Drug Info

Quick Facts

Related News